A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis

Ann Rheum Dis. 2008 Dec;67(12):1791-2. doi: 10.1136/ard.2007.086892.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / genetics*
  • Female
  • Genetic Markers
  • Humans
  • Infliximab
  • Male
  • Middle Aged
  • Prospective Studies
  • Receptors, IgG / genetics*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • FCGR3A protein, human
  • Genetic Markers
  • Receptors, IgG
  • Infliximab